1. FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results. News release. FDA. April 13, 2026.
Two classic translational blocks are compounded by an execution gap characterized by weak cross-functional mobilization, slow ...
How AI agents are solving the technical complexity of modern study builds and eliminating manual bottlenecks. Why strategic ...
In today's ACT Brief, we explore biological and dosing considerations for basket trial designs, how human-relevant data ...
In today's ACT Brief, we examine Thermo Fisher's expanded real-world data access through HealthVerity, how FHIR-based ...
In this Q&A, Jenna DiRito, PhD, COO and co-founder of Revalia Bio, discusses how earlier, human-relevant data is reshaping go ...
In this video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, ...
In today's ACT Brief, we explore why clinical trial diversity requires protocol redesign from the outset, the highest-impact ...
In today's ACT Brief, we explore industry perspectives on operational and methodological shifts defining 2026, how agentic AI ...
A collaborative study by the Tufts Center for the Study of Drug Development and CRIO identifies protocol interpretation and source document preparation as an understudied yet significant bottleneck in ...
In today's ACT Brief, we explore how FDA evaluates effectiveness for ultra-rare individualized therapies, the agency's ...
In today's ACT Brief, we examine how protocol interpretation and source document preparation delay study startup, how the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results